LaunchCapital, CI invest $1.3M in Affinimark
Affinimark Technologies Inc., a New Haven, Conn., company that develops point-of-care tests for cerebrospinal leaks has received a $1,359,394 investment by the quasi-public agency Connecticut Innovations and LaunchCapital.
Affinimark has developed the Cerebrostrip, which the company says is an an easy-to-use test strip format to detect the presence of certain cerebrospinal fluid antigens in fluid taken from a surgical site or the site of a patient injury. It is designed to replace the current system in which a physician suspecting a cerebrospinal fluid leak collects a relatively large amount of fluid and sends it to a laboratory for testing, and then waits several days for the test results. The company plans to use the funds to complete the clinical and regulatory development of the test technology.